Novartis has announced results for Cosentyx from a pooled-analysis that shows sustained improvement in signs and symptoms of psoriatic arthritis, particularly for American College of Rheumatology 50 (ACR50), and Psoriasis Area and Severity Index (PASI) severity endpoints.
The abstract, which is being presented at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) in Madrid, shows that ACR 50, PASI 90 and Quality of life response with secukinumab at month four in patients with and without enthesitis is sustained for up to two years.
The new data compare the effects of secukinumab treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients.
The pooled analysis results of two Phase 3 studies show that patients treated with Cosentyx had a faster time to complete resolution of enthesitis than those receiving placebo.
The results strengthen the position of Cosentyx as a rapid and long-lasting complete treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, with over 250,000 patients treated worldwide.
Eric Hughes, Global Development Unit Head, Immunology, Hepatology & Dermatology, Novartis, said: “We are pleased that the data show rapid and sustained improvement across two years in the signs and symptoms of psoriatic arthritis with Cosentyx, regardless of whether patients have enthesitis or not.
“Psoriatic arthritis is complex with multiple manifestations driving patient symptoms including enthesitis, which is often associated with more severe disease. We are striving to reimagine care in immuno-dermatology and across all manifestations of psoriatic disease to support patients and help them achieve improved quality of life.”